Nanovibronix, Inc. (NASDAQ:FEED) Short Interest Down 61.2% in May

Nanovibronix, Inc. (NASDAQ:FEED) saw a large decrease in short interest during the month of May. As of May 29th, there was short interest totaling 63,342 shares, a decrease of 61.2% from the May 14th total of 163,391 shares. Based on an average trading volume of 280,633 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.1% of the shares of the stock are short sold.

Nanovibronix Stock Performance

FEED stock traded down $0.05 during mid-day trading on Friday, reaching $0.83. 459,225 shares of the stock traded hands, compared to its average volume of 1,769,525. Nanovibronix has a 52-week low of $0.72 and a 52-week high of $17.40. The stock has a market capitalization of $5.05 million, a P/E ratio of -0.09 and a beta of 1.51. The stock has a fifty day moving average of $1.23.

Nanovibronix (NASDAQ:FEED) last posted its quarterly earnings data on Monday, May 18th. The company reported ($6.88) EPS for the quarter. Nanovibronix had a negative net margin of 923.20% and a negative return on equity of 54.25%. The firm had revenue of $0.65 million for the quarter.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on FEED. Weiss Ratings reissued a “sell (e+)” rating on shares of Nanovibronix in a report on Friday, April 24th. Wall Street Zen raised shares of Nanovibronix from a “strong sell” rating to a “sell” rating in a report on Tuesday, April 28th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Nanovibronix currently has an average rating of “Sell”.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.